AU603950B1 - Immunity memory cell suspension and method of preparing same - Google Patents
Immunity memory cell suspension and method of preparing same Download PDFInfo
- Publication number
- AU603950B1 AU603950B1 AU32747/89A AU3274789A AU603950B1 AU 603950 B1 AU603950 B1 AU 603950B1 AU 32747/89 A AU32747/89 A AU 32747/89A AU 3274789 A AU3274789 A AU 3274789A AU 603950 B1 AU603950 B1 AU 603950B1
- Authority
- AU
- Australia
- Prior art keywords
- cells
- immunity
- cell suspension
- immunity memory
- antibody
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Ceased
Links
- 230000036039 immunity Effects 0.000 title claims description 223
- 230000015654 memory Effects 0.000 title claims description 196
- 239000006285 cell suspension Substances 0.000 title claims description 148
- 238000000034 method Methods 0.000 title claims description 54
- 210000004027 cell Anatomy 0.000 claims description 344
- 239000000427 antigen Substances 0.000 claims description 74
- 102000036639 antigens Human genes 0.000 claims description 74
- 108091007433 antigens Proteins 0.000 claims description 74
- 230000001717 pathogenic effect Effects 0.000 claims description 35
- 210000001744 T-lymphocyte Anatomy 0.000 claims description 33
- 244000052769 pathogen Species 0.000 claims description 26
- 210000002966 serum Anatomy 0.000 claims description 25
- 238000001042 affinity chromatography Methods 0.000 claims description 24
- 239000000725 suspension Substances 0.000 claims description 24
- 238000002360 preparation method Methods 0.000 claims description 21
- 239000011491 glass wool Substances 0.000 claims description 18
- 239000000203 mixture Substances 0.000 claims description 17
- 239000004677 Nylon Substances 0.000 claims description 15
- 229920001778 nylon Polymers 0.000 claims description 15
- 239000003463 adsorbent Substances 0.000 claims description 12
- 238000000576 coating method Methods 0.000 claims description 12
- 239000007787 solid Substances 0.000 claims description 12
- 239000011248 coating agent Substances 0.000 claims description 10
- 241000894007 species Species 0.000 claims description 8
- 230000000295 complement effect Effects 0.000 claims description 7
- 230000002085 persistent effect Effects 0.000 claims description 7
- 230000002285 radioactive effect Effects 0.000 claims description 6
- 230000005855 radiation Effects 0.000 claims description 5
- 230000002401 inhibitory effect Effects 0.000 claims description 4
- 230000000415 inactivating effect Effects 0.000 claims description 3
- 238000007747 plating Methods 0.000 claims description 2
- 238000011160 research Methods 0.000 claims description 2
- 241000700159 Rattus Species 0.000 description 26
- 239000002609 medium Substances 0.000 description 23
- 241000699666 Mus <mouse, genus> Species 0.000 description 21
- 238000012360 testing method Methods 0.000 description 20
- 210000004698 lymphocyte Anatomy 0.000 description 18
- 201000011510 cancer Diseases 0.000 description 17
- 210000001519 tissue Anatomy 0.000 description 17
- 238000005119 centrifugation Methods 0.000 description 16
- 238000006243 chemical reaction Methods 0.000 description 13
- 206010028980 Neoplasm Diseases 0.000 description 12
- 210000003719 b-lymphocyte Anatomy 0.000 description 12
- 201000010099 disease Diseases 0.000 description 12
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 12
- 210000000952 spleen Anatomy 0.000 description 12
- 230000000890 antigenic effect Effects 0.000 description 11
- 208000035473 Communicable disease Diseases 0.000 description 10
- 239000011521 glass Substances 0.000 description 10
- 208000015181 infectious disease Diseases 0.000 description 10
- 239000000243 solution Substances 0.000 description 9
- 239000001963 growth medium Substances 0.000 description 8
- 239000006228 supernatant Substances 0.000 description 8
- 230000003612 virological effect Effects 0.000 description 8
- 230000001580 bacterial effect Effects 0.000 description 7
- 230000001605 fetal effect Effects 0.000 description 7
- 210000005259 peripheral blood Anatomy 0.000 description 7
- 239000011886 peripheral blood Substances 0.000 description 7
- 230000002265 prevention Effects 0.000 description 7
- 241000283707 Capra Species 0.000 description 6
- 241000283973 Oryctolagus cuniculus Species 0.000 description 6
- 229910019142 PO4 Inorganic materials 0.000 description 6
- 210000001840 diploid cell Anatomy 0.000 description 6
- 238000011534 incubation Methods 0.000 description 6
- NBIIXXVUZAFLBC-UHFFFAOYSA-K phosphate Chemical compound [O-]P([O-])([O-])=O NBIIXXVUZAFLBC-UHFFFAOYSA-K 0.000 description 6
- 239000010452 phosphate Substances 0.000 description 6
- 239000011369 resultant mixture Substances 0.000 description 6
- 239000012266 salt solution Substances 0.000 description 6
- GUTLYIVDDKVIGB-OUBTZVSYSA-N Cobalt-60 Chemical compound [60Co] GUTLYIVDDKVIGB-OUBTZVSYSA-N 0.000 description 5
- 241000607142 Salmonella Species 0.000 description 5
- 230000000694 effects Effects 0.000 description 5
- 229910000831 Steel Inorganic materials 0.000 description 4
- 210000004369 blood Anatomy 0.000 description 4
- 239000008280 blood Substances 0.000 description 4
- 239000000835 fiber Substances 0.000 description 4
- 230000001900 immune effect Effects 0.000 description 4
- 238000000338 in vitro Methods 0.000 description 4
- 210000002540 macrophage Anatomy 0.000 description 4
- 230000011278 mitosis Effects 0.000 description 4
- 239000007858 starting material Substances 0.000 description 4
- 239000010959 steel Substances 0.000 description 4
- 238000006467 substitution reaction Methods 0.000 description 4
- 238000002255 vaccination Methods 0.000 description 4
- 241000725630 Ectromelia virus Species 0.000 description 3
- 241000711408 Murine respirovirus Species 0.000 description 3
- 101100438963 Mus musculus Cd8b gene Proteins 0.000 description 3
- 241000606860 Pasteurella Species 0.000 description 3
- 241000194017 Streptococcus Species 0.000 description 3
- 230000001747 exhibiting effect Effects 0.000 description 3
- 230000006054 immunological memory Effects 0.000 description 3
- 238000004519 manufacturing process Methods 0.000 description 3
- 230000003449 preventive effect Effects 0.000 description 3
- 230000004044 response Effects 0.000 description 3
- 238000000926 separation method Methods 0.000 description 3
- 230000000638 stimulation Effects 0.000 description 3
- 210000001541 thymus gland Anatomy 0.000 description 3
- 210000004881 tumor cell Anatomy 0.000 description 3
- 241000894006 Bacteria Species 0.000 description 2
- CURLTUGMZLYLDI-UHFFFAOYSA-N Carbon dioxide Chemical compound O=C=O CURLTUGMZLYLDI-UHFFFAOYSA-N 0.000 description 2
- KCXVZYZYPLLWCC-UHFFFAOYSA-N EDTA Chemical compound OC(=O)CN(CC(O)=O)CCN(CC(O)=O)CC(O)=O KCXVZYZYPLLWCC-UHFFFAOYSA-N 0.000 description 2
- 241001465754 Metazoa Species 0.000 description 2
- 101100438957 Mus musculus Cd8a gene Proteins 0.000 description 2
- 239000012980 RPMI-1640 medium Substances 0.000 description 2
- 206010039438 Salmonella Infections Diseases 0.000 description 2
- 230000024932 T cell mediated immunity Effects 0.000 description 2
- 241000700605 Viruses Species 0.000 description 2
- 230000002411 adverse Effects 0.000 description 2
- 238000013019 agitation Methods 0.000 description 2
- 208000022362 bacterial infectious disease Diseases 0.000 description 2
- 239000013078 crystal Substances 0.000 description 2
- 230000002554 disease preventive effect Effects 0.000 description 2
- 230000000763 evoking effect Effects 0.000 description 2
- 238000002474 experimental method Methods 0.000 description 2
- 239000012634 fragment Substances 0.000 description 2
- 230000004727 humoral immunity Effects 0.000 description 2
- 230000008076 immune mechanism Effects 0.000 description 2
- 230000028993 immune response Effects 0.000 description 2
- 239000007788 liquid Substances 0.000 description 2
- 206010033675 panniculitis Diseases 0.000 description 2
- 230000002028 premature Effects 0.000 description 2
- 238000012545 processing Methods 0.000 description 2
- 206010039447 salmonellosis Diseases 0.000 description 2
- DAEPDZWVDSPTHF-UHFFFAOYSA-M sodium pyruvate Chemical compound [Na+].CC(=O)C([O-])=O DAEPDZWVDSPTHF-UHFFFAOYSA-M 0.000 description 2
- 210000004304 subcutaneous tissue Anatomy 0.000 description 2
- 208000035143 Bacterial infection Diseases 0.000 description 1
- BVKZGUZCCUSVTD-UHFFFAOYSA-M Bicarbonate Chemical compound OC([O-])=O BVKZGUZCCUSVTD-UHFFFAOYSA-M 0.000 description 1
- NLZUEZXRPGMBCV-UHFFFAOYSA-N Butylhydroxytoluene Chemical compound CC1=CC(C(C)(C)C)=C(O)C(C(C)(C)C)=C1 NLZUEZXRPGMBCV-UHFFFAOYSA-N 0.000 description 1
- 102000009485 HLA-D Antigens Human genes 0.000 description 1
- 108010048896 HLA-D Antigens Proteins 0.000 description 1
- 102000006354 HLA-DR Antigens Human genes 0.000 description 1
- 108010058597 HLA-DR Antigens Proteins 0.000 description 1
- 241000726041 Human respirovirus 1 Species 0.000 description 1
- DGAQECJNVWCQMB-PUAWFVPOSA-M Ilexoside XXIX Chemical compound C[C@@H]1CC[C@@]2(CC[C@@]3(C(=CC[C@H]4[C@]3(CC[C@@H]5[C@@]4(CC[C@@H](C5(C)C)OS(=O)(=O)[O-])C)C)[C@@H]2[C@]1(C)O)C)C(=O)O[C@H]6[C@@H]([C@H]([C@@H]([C@H](O6)CO)O)O)O.[Na+] DGAQECJNVWCQMB-PUAWFVPOSA-M 0.000 description 1
- 241000699670 Mus sp. Species 0.000 description 1
- 240000004808 Saccharomyces cerevisiae Species 0.000 description 1
- ATJFFYVFTNAWJD-UHFFFAOYSA-N Tin Chemical compound [Sn] ATJFFYVFTNAWJD-UHFFFAOYSA-N 0.000 description 1
- 206010044565 Tremor Diseases 0.000 description 1
- 210000000683 abdominal cavity Anatomy 0.000 description 1
- 230000001464 adherent effect Effects 0.000 description 1
- 238000013459 approach Methods 0.000 description 1
- 210000001367 artery Anatomy 0.000 description 1
- 238000003556 assay Methods 0.000 description 1
- 229910002092 carbon dioxide Inorganic materials 0.000 description 1
- 239000001569 carbon dioxide Substances 0.000 description 1
- 150000001768 cations Chemical class 0.000 description 1
- 238000004587 chromatography analysis Methods 0.000 description 1
- 230000001419 dependent effect Effects 0.000 description 1
- 239000000284 extract Substances 0.000 description 1
- 230000002779 inactivation Effects 0.000 description 1
- 150000002500 ions Chemical class 0.000 description 1
- 210000002751 lymph Anatomy 0.000 description 1
- 210000001165 lymph node Anatomy 0.000 description 1
- 229940049964 oleate Drugs 0.000 description 1
- ZQPPMHVWECSIRJ-KTKRTIGZSA-N oleic acid Chemical compound CCCCCCCC\C=C/CCCCCCCC(O)=O ZQPPMHVWECSIRJ-KTKRTIGZSA-N 0.000 description 1
- 230000002093 peripheral effect Effects 0.000 description 1
- 239000004033 plastic Substances 0.000 description 1
- 239000000047 product Substances 0.000 description 1
- 230000000717 retained effect Effects 0.000 description 1
- 239000002356 single layer Substances 0.000 description 1
- 229910052708 sodium Inorganic materials 0.000 description 1
- 239000011734 sodium Substances 0.000 description 1
- 229940054269 sodium pyruvate Drugs 0.000 description 1
- 238000001179 sorption measurement Methods 0.000 description 1
- 210000004989 spleen cell Anatomy 0.000 description 1
- 238000005507 spraying Methods 0.000 description 1
- 230000008791 toxic response Effects 0.000 description 1
- 210000003462 vein Anatomy 0.000 description 1
- 210000000264 venule Anatomy 0.000 description 1
- 238000005406 washing Methods 0.000 description 1
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 1
- 210000002268 wool Anatomy 0.000 description 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N5/00—Undifferentiated human, animal or plant cells, e.g. cell lines; Tissues; Cultivation or maintenance thereof; Culture media therefor
- C12N5/0081—Purging biological preparations of unwanted cells
- C12N5/0087—Purging against subsets of blood cells, e.g. purging alloreactive T cells
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K40/00—Cellular immunotherapy
- A61K40/10—Cellular immunotherapy characterised by the cell type used
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K40/00—Cellular immunotherapy
- A61K40/40—Cellular immunotherapy characterised by antigens that are targeted or presented by cells of the immune system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K40/00—Cellular immunotherapy
- A61K40/40—Cellular immunotherapy characterised by antigens that are targeted or presented by cells of the immune system
- A61K40/41—Vertebrate antigens
- A61K40/42—Cancer antigens
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N5/00—Undifferentiated human, animal or plant cells, e.g. cell lines; Tissues; Cultivation or maintenance thereof; Culture media therefor
- C12N5/06—Animal cells or tissues; Human cells or tissues
- C12N5/0602—Vertebrate cells
- C12N5/0634—Cells from the blood or the immune system
- C12N5/0636—T lymphocytes
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K2239/00—Indexing codes associated with cellular immunotherapy of group A61K40/00
- A61K2239/31—Indexing codes associated with cellular immunotherapy of group A61K40/00 characterized by the route of administration
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K2239/00—Indexing codes associated with cellular immunotherapy of group A61K40/00
- A61K2239/38—Indexing codes associated with cellular immunotherapy of group A61K40/00 characterised by the dose, timing or administration schedule
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Engineering & Computer Science (AREA)
- General Health & Medical Sciences (AREA)
- Veterinary Medicine (AREA)
- Organic Chemistry (AREA)
- Animal Behavior & Ethology (AREA)
- Public Health (AREA)
- Biomedical Technology (AREA)
- Chemical & Material Sciences (AREA)
- Wood Science & Technology (AREA)
- Genetics & Genomics (AREA)
- Zoology (AREA)
- Epidemiology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Biotechnology (AREA)
- Immunology (AREA)
- Hematology (AREA)
- Microbiology (AREA)
- General Engineering & Computer Science (AREA)
- Biochemistry (AREA)
- Cell Biology (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Pharmacology & Pharmacy (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Medicinal Chemistry (AREA)
- General Chemical & Material Sciences (AREA)
- Virology (AREA)
- Communicable Diseases (AREA)
- Oncology (AREA)
- Molecular Biology (AREA)
- Medicines Containing Material From Animals Or Micro-Organisms (AREA)
- Micro-Organisms Or Cultivation Processes Thereof (AREA)
- Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| JP63300726A JP2639834B2 (ja) | 1988-11-30 | 1988-11-30 | 免疫記憶細胞懸濁液およびその調製方法 |
| CA000596787A CA1333887C (en) | 1988-11-30 | 1989-04-14 | Immunity memory cell suspension and method of preparing same |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| AU603950B1 true AU603950B1 (en) | 1990-11-29 |
Family
ID=25672621
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| AU32747/89A Ceased AU603950B1 (en) | 1988-11-30 | 1989-04-12 | Immunity memory cell suspension and method of preparing same |
Country Status (7)
| Country | Link |
|---|---|
| JP (1) | JP2639834B2 (enrdf_load_stackoverflow) |
| AU (1) | AU603950B1 (enrdf_load_stackoverflow) |
| CA (1) | CA1333887C (enrdf_load_stackoverflow) |
| CH (1) | CH678337A5 (enrdf_load_stackoverflow) |
| DE (1) | DE3913438A1 (enrdf_load_stackoverflow) |
| FR (1) | FR2646778B1 (enrdf_load_stackoverflow) |
| GB (1) | GB2230790B (enrdf_load_stackoverflow) |
Families Citing this family (4)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US6143508A (en) * | 1989-06-29 | 2000-11-07 | Rhone-Poulenc Rorer Pharmaceuticals Inc. | Device and process for cell capture and recovery |
| CA1340565C (en) | 1989-06-29 | 1999-05-25 | Thomas B. Okarma | Device and process for cell capture and recovery |
| SE467498B (sv) * | 1990-11-20 | 1992-07-27 | Vera Stejskal | Foerfarande foer in vitro analys av kvicksilverallergier |
| DE19925405C2 (de) * | 1999-06-02 | 2003-02-13 | Bieger Wilfried W | Verfahren zum Nachweis von spezifisch antigenreaktiven Lymphozyten sowie ein Nachweis-Kit zur Durchführung dieses Verfahrens |
Citations (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| EP0077571A2 (en) * | 1981-10-19 | 1983-04-27 | Ajinomoto Co., Inc. | Process for producing a lymphokine |
Family Cites Families (2)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| JPH02502424A (ja) * | 1987-03-11 | 1990-08-09 | ザ・チルドレンズ・ホスピタル，インコーポレイテッド | 抗原特異的ｔセルラインの調製法並びに治療のためのその使用 |
| JPS63300727A (ja) * | 1987-05-29 | 1988-12-07 | 古形 勝 | 健康タワシ |
-
1988
- 1988-11-30 JP JP63300726A patent/JP2639834B2/ja not_active Expired - Lifetime
-
1989
- 1989-04-12 GB GB8908241A patent/GB2230790B/en not_active Expired - Fee Related
- 1989-04-12 AU AU32747/89A patent/AU603950B1/en not_active Ceased
- 1989-04-14 CA CA000596787A patent/CA1333887C/en not_active Expired - Fee Related
- 1989-04-24 DE DE3913438A patent/DE3913438A1/de active Granted
- 1989-05-11 FR FR898906179A patent/FR2646778B1/fr not_active Expired - Fee Related
- 1989-05-17 CH CH1833/89A patent/CH678337A5/fr not_active IP Right Cessation
Patent Citations (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| EP0077571A2 (en) * | 1981-10-19 | 1983-04-27 | Ajinomoto Co., Inc. | Process for producing a lymphokine |
Also Published As
| Publication number | Publication date |
|---|---|
| JPH02150274A (ja) | 1990-06-08 |
| CH678337A5 (enrdf_load_stackoverflow) | 1991-08-30 |
| FR2646778A1 (fr) | 1990-11-16 |
| GB2230790A (en) | 1990-10-31 |
| GB2230790B (en) | 1993-04-21 |
| GB8908241D0 (en) | 1989-05-24 |
| DE3913438A1 (de) | 1990-10-25 |
| CA1333887C (en) | 1995-01-10 |
| FR2646778B1 (fr) | 1991-08-23 |
| JP2639834B2 (ja) | 1997-08-13 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| US4444887A (en) | Process for making human antibody producing B-lymphocytes | |
| DE69430315T2 (de) | Methoden zur (ex vivo) therapie mittels peptid - bestueckten antigen - praesentierenden zellen zur aktivierung von ctl | |
| Holm | Lysis of antibody-treated human erythrocytes by human leukocytes and macrophages in tissue culture | |
| US4224404A (en) | Production of specific immune nucleic acids cell dialysates and antibodies | |
| Holmberg et al. | Natural killer activity in the peritoneal exudates of mice infected with Listeria monocytogenes: characterization of the natural killer cells by using a monoclonal rat anti-murine macrophage antibody (M1/70). | |
| JPH11505512A (ja) | マクロファージを調製する方法、ならびにそのためのキットおよび組成物 | |
| David et al. | Helper factors derived from autologous mixed lymphocyte cultures | |
| EP2859092B1 (en) | Therapeutic vaccine for treatment of diabetes type 1 in children, application of the cell sorter and the method of multiplying treg cells to produce therapeutic vaccine for treatment of diabetes type 1 | |
| JPH06205671A (ja) | 形質転換細胞の抽出および培養ならびにそれらに対する抗体の製造 | |
| CN109402054A (zh) | 一种cd4+记忆性t淋巴细胞的扩增培养方法 | |
| JPS5829714A (ja) | 血清不含およびミトゲン不含ｔ細胞生長因子およびその製造法 | |
| Shek et al. | Mitogen stimulation of rabbit spleen cells before and after complement-mediated cell kill with an antiserum directed against the thymus antigen RTLA | |
| Robert et al. | Inhibition of the mixed lymphocyte reaction by sera from multipara | |
| AU603950B1 (en) | Immunity memory cell suspension and method of preparing same | |
| AU632999B2 (en) | Method and means for immuno-stimulating blood treatment with a mitogen | |
| BE1001517A5 (fr) | Heterohybridomes produisant des anticorps monoclonaux anti-rhesus d humains. | |
| Hollander et al. | Allogeneic cytolysis of reconstituted membrane vesicles. | |
| Wasserman et al. | Antibody-induced in vitro lymphocyte cytotoxicity in Hashimoto thyroiditis | |
| Jachertz et al. | Information carried by the DNA released by antigen-stimulated lymphocytes | |
| Kyoizumi et al. | A cloned cell line, Mk1, possessing Ia antigens and accessory cell activity. | |
| JP2639835B2 (ja) | 免疫記憶細胞懸濁液の調製方法 | |
| Kourilsky et al. | A qualitative study of normal leukocyte antigens of human leukemic leukoblasts | |
| Drury et al. | Isolation of Θ-Isoantigen-Negative, Antibody-Inhibiting Cells from Normal Mouse Bone Marrow According to Their Density and Surface-Adherent Properties | |
| SILVESTRI et al. | Positive Selection of CD34+ Cells: A Short Review of the Immunoadsorption Methods Currently Available for Experimental and Clinical Use: Report on the" 2nd European Workshop on Stem Cell Methodology," Mulhouse, France, May 3-7, 1993 | |
| Golub et al. | Cellular reactions against Burkitt lymphoma cells. II. Effector cells obtained by allogeneic stimulation in mixed leukocyte cultures |